Method comparison of plasma and CSF GFAP immunoassays across multiple platforms
Despite strong correlations, substantial method-dependent biases indicate that GFAP measurements across different immunoassay platforms need to be standardized to ensure harmonization and reliable clinical application of GFAP as a biomarker.
Authors
- Sofia Rasch
- Hlin Kvartsberg (ORCID: https://orcid.org/0000-0002-4481-508X)
- Burak Arslan (ORCID: https://orcid.org/0000-0001-7229-3226)
- Ulf Andréasson (ORCID: https://orcid.org/0000-0001-8622-052X)
- Henrik Zetterberg
- Kaj Blennow
- Elzbieta Rembeza
Institutions
- University of Science and Technology of China (CN)
- University of Wisconsin–Madison (US)
- Sahlgrenska University Hospital (SE)
- Sorbonne Université (FR)
- Institute for Neurodegenerative Disorders (US)
- Pitié-Salpêtrière Hospital (FR)
- UK Dementia Research Institute (GB)
- University of Wisconsin Health (US)
- MRC Prion Unit (GB)
- Institut du Cerveau (FR)
- University College London (GB)
- University of Gothenburg (SE)
Publication Details
- Journal
- Clinical Chemistry and Laboratory Medicine (CCLM)
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1515/cclm-2025-0667
- Citations
- 2
- Primary Topic
- S100 Proteins and Annexins
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- Eli Lilly and Company
- Sanofi
- Biogen
- Familjen Erling-Perssons Stiftelse
- Cure Alzheimer's Fund
- Stiftelsen för Gamla Tjänarinnor
- EU Joint Programme – Neurodegenerative Disease Research
- Prothena
- Apellis Pharmaceuticals
- National Institute for Health and Care Research
- University College London
- European Commission
- Eisai
- Hjärnfonden
- Novo Nordisk
- Vetenskapsrådet
- Sahlgrenska Universitetssjukhuset
- Göteborgs Universitet
- Siemens Healthineers
- Julius Clinical
- UK Dementia Research Institute
- HORIZON EUROPE Framework Programme